ALTH Allos Therapeutics, Inc. (MM)

Allos Therapeutics Files Shelf Registration Statement WESTMINSTER, Colo., March 5 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. announced today that it has filed a Form S-3 shelf registration with the Securities and Exchange Commission (SEC). The shelf registration, when declared effective by the SEC, will allow the company to raise up to $75 million through the sale of various securities in one or more offerings in the future. Specific terms and prices will be determined at the time of any offering. A registration statement relating to the securities listed in the shelf registration has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy such securities be accepted, prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A written prospectus, when available, meeting the requirements of Section 10 of the Securities Act of 1933, as amended, may be obtained fromthe company at 11080 CirclePoint Road, Suite 200, Westminster, Colorado 80020, Attention: Investor Relations. Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, RSR13, is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX, an injectable small molecule chemotherapeutic agent that has a superior potency and toxicity profile relative to methotrexate and other dihydrofolate reductase, or DHFR, inhibitors. For more information, please visit the company's web site at: http://www.allos.com/. This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the sale of securities under the shelf registration statement. Such statements are only predictions and the company may be unable to complete any sale of securities under the shelf registration statement. Factors that may cause such differences include market conditions and others that are more fully discussed in the company's periodic reports and other filings with the SEC. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Monique M. Greer VP, Corporate Communications and Investor Relations of Allos Therapeutics, Inc., +1-720-540-5241, Web site: http://www.allos.com/

Copyright